EUCTR2018-000127-14-AT进行中（未招募）1 期
INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies - INFORM2 NivEnt
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 128
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Children and adolescents with refractory/relapsed/progressive high-risk
- •-CNS tumors: medulloblastoma, ependymoma, ATRT, ETMR, pediatric high grade glioma (including DIPG) or other pediatric embryonal CNS tumors
- •-solid tumors: neuroblastoma, nephroblastoma, rhabdoid tumor, embryonal or alveolar rhabdomyosarcoma or other embryonal small round blue cell tumors including pediatric type (bone) sarcoma, or other pediatric type solid tumors
- •Children and adolescents with newly diagnosed high grade glioma (HGG) in the context of a constitutional mismatch repair deficiency syndrome after maximum safe surgical resection with no established standard of care treatment option with curative intention available.
- •-No standard of care treatment available
- •-Age at registration = 6 to = 21 years.
- •-Molecular analysis for biomarker identification (SNV load, PDL1 mRNA expression, MYC/N amplification) in laboratories complying with DIN EN ISO/IEC 17025 or similar via INFORM molecular diagnostic platform or equivalently valid molecular pipeline.
- •-Biomarker determined using whole exome sequencing (SNV load), RNA-sequencing (PDL1 mRNA expression) and whole genome or whole exome sequencing (MYC/N amplification).
- •-In case molecular analysis was not performed via INFORM Registry molecular pipeline: transfer of molecular data (whole exome and RNA sequencing)
- •-Time between biopsy/puncture/resection of the current refractory/relapsed/progressive tumor and registration = 24 weeks. In patients receiving therapy not impacting biomarker stratification, time between biopsy/puncture/resection of the current refractory/relapsed/progressive tumor and registration of = 36 weeks is allowed.
- •-Disease that is measurable as defined by RANO criteria or RECIST v1.1 (as appropriate).
- •-Life expectancy > 3 months, sufficient general condition score (Lansky = 70 or Karnofsky = 70). Transient states like infections can be accepted, and also stable disabilities resulting from disease/surgery (hemiparesis, amputations etc.) can be accepted and will not be considered for Lansky/Karnofsky assessments.
- •-Laboratory requirements:
- •-Hematology:absolute granulocytes= 1.0 × 109/l (unsupported)
- •platelets= 100 × 109/l&stable
- •hemoglobin = 8 g/dl or = 4,96 nmol/L
- •-Biochemistry:Total bilirubin= 1.5 x upper limit of normal (ULN)
- •AST(SGOT)= 3.0 x ULN
- •ALT(SGPT)= 3.0 x ULN
- •serum creatinine= 1.5 x ULN for age
- •-ECG: normal QTc interval = 480 msec
- •-Patient is able to swallow oral study medication
- •-Ability of patient and/or legal representative(s) to understand the character and individual consequences of clinical trial
- •-Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to initiation of treatment. Sexually active women of childbearing potential must agree to use acceptable and appropriate contraception during the study and for at least 6 months after the last study treatment administration. Sexually active male patients must agree to use a condom during the study and for at least 7 months after the last study treatment administration.
- •-Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •-Before patient screening and registration, written informed consent, also concerning data and blood tr
排除标准
- •-Patients with CNS tumors or metastases who are neurologically unstable despite adequate treatment (e.g. convulsions).
- •-Patients with low-grade gliomas or tumors of unknown malignant potential are not eligible
- •-Evidence of > Grade 1 recent CNS hemorrhage on the baseline MRI scan.
- •-Participants with bulky CNS tumor on imaging are ineligible; bulky tumor is defined as:
- •-Tumor with any evidence of uncal herniation or severe midline shift
- •-Tumor with diameter of > 6 cm in one dimension on contrast-enhanced MRI
- •-Tumor that in the opinion of the investigator, shows significant mass effect
- •-Previous allogeneic bone marrow, stem cell or organ transplantation
- •-Diagnosis of immunodeficiency
- •-Diagnosis of prior or active autoimmune disease
- •-Evidence of interstitial lung disease
- •-Any contraindication to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the investigator, would preclude adequate absorption.
- •-Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to study treatment. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •-Clinically significant, uncontrolled heart disease
- •-Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.
- •-Any anticancer therapy (e.g., chemotherapy, HDACi (including valproic acid), DNA methyltransferase inhibitors, other immunotherapy, targeted therapy, biological response modifiers, endocrine anticancer therapy or radiotherapy) within 2 weeks or at least 5 half-lives (whichever is longer) of study drug administration.
- •-Radiologically confirmed radiotherapy induced pseudoprogression in CNS tumors
- •-Traditional herbal medicines; these therapies are not fully studied and their use may result in unanticipated drug-drug interactions that may cause or confound the assessment of toxicity. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. For information on CYP substrates and P-gp inhibitors or inducers see section 5.8.
- •-History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form (including benzamide) of the investigational medicinal product
- •-Participation in other ongoing clinical trials.
- •-Pregnant or lactating females.
- •-Presence of underlying medical condition (e.g. gastrointestinal disorders or electrolyte disturbances) that in the opinion of the Investigator or Sponsor could adversely affect the ability of the subject to comply with or tolerate study pro
研究者
相似试验
进行中（未招募）
1 期
INFORM2 NivEnt, an european clinical trial to determine a safe dose and signs of efficacy of the combination treatment of novolumab and entinostat in children and adolescents with refractory high-risk malignanciesEUCTR2018-000127-14-SEHeidelberg University Hospital91
招募中
2 期
INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignanciesrefractory or progressive high-risk solide tumors or CNS tmors10027655NL-OMON55442Heidelberg University Hospital, Hopp Children's Cancer Center Heidelberg (KiTZ)20
进行中（未招募）
1 期
INFORM2 NivEnt, an european clinical trial to determine a safe dose and signs of efficacy of the combination treatment of novolumab and entinostat in children and adolescents with refractory high-risk malignanciesEUCTR2018-000127-14-NLHeidelberg University Hospital128
进行中（未招募）
1 期
INFORM2 NivEnt, an european clinical trial to determine a safe dose and signs of efficacy of the combination treatment of novolumab and entinostat in children and adolescents with refractory high-risk malignanciesThis trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CNS tumors. Thus, this trial focuses on the pediatric population in 4 biomarker-defined cohorts, for which there is no standard of care treatment available.EUCTR2018-000127-14-DEHeidelberg University Hospital91
进行中（未招募）
1 期
INFORM2 NivEnt, an european clinical trial to determine a safe dose and signs of efficacy of the combination treatment of novolumab and entinostat in children and adolescents with refractory high-risk malignanciesThis trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CNS tumors. Thus, this trial focuses on the pediatric population in 4 biomarker-defined cohorts, for which there is no standard of care treatment available.EUCTR2018-000127-14-FRHeidelberg University Hospital128